HIV won't be much, NASH is not showing good data, Cancer and NASH will take years. Most of the 30+ indications haven't had animal data let alone proof of concept. The company is going to be desperately diluting the hell out of its shareholders to stay alive. As the 200 million isn't going to make it through mid-2022 and then more and more will be required all coming out of shareholders pockets. Not going to be a pretty picture, but you can dream.
Market Data 
Markets 
AI
